Similarly, in syngeneic immunocompetent mouse models of ovarian cancer and colon cancer lacking mutations in homologous recombination repair pathway genes, talazoparib, PARPi with potent PARP1 inhibitory activity comparable to olaparib, was reported to activate the cGAS‐STING pathway and augment the infiltration of CD8+ T cells into tumors, leading to the effective overcoming of the resistance to anti‐PD‐L1 antibody by combination treatment [13]. Here, CD8A is linked to ovarian cancer.